Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2022.
Financials
Financial year 2025
PHARBIOMED from Brussel, company number BE0597824559, closed financial year 2025 with a result of € 258,313 after tax. For that financial year PHARBIOMED recorded a gross margin of € 423,562 and equity of € 235,802. Compared with financial year 2024, the result moved from € 71,213 to € 258,313. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 235,802
▲ € 208,313 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 258,313
▲ 263% vs 2024
Profit after tax over the fiscal year.
€ 102,546
▲ 76% vs 2024
Cash and bank balances on the last day of the fiscal year.
€ 50,000 paid out
19 % of the profit went to the shareholders, the rest stayed in the company.
People and assets in 2025
€ 61,822
▲ 67% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,157
▼ 26% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 4,543
▼ 8% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 88,995
▲ 118% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 137,750 | € 158,324 | € 148,672 | € 423,562 | ▲ 185% |
| Profit after taxes | € 50,289 | € 63,874 | € 71,213 | € 258,313 | ▲ 263% |
| Equity | € 246,781 | € 27,489 | € 27,489 | € 235,802 | ▲ € 208,313 |
| Total debts | € 140,601 | € 122,320 | € 142,912 | € 134,061 | ▼ 6% |
| Cash | € 259,082 | € 29,399 | € 58,152 | € 102,546 | ▲ 76% |
| Retained profit | € 240,581 | € 8,889 | € 8,889 | € 217,202 | ▲ € 208,313 |
| Dividend | € 86,000 | € 64,566 | € 71,213 | € 50,000 | ▼ 30% |
| Balance sheet total | € 387,382 | € 149,809 | € 170,401 | € 369,863 | ▲ 117% |
Key figures of PHARBIOMED, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARBIOMED?
What happened at PHARBIOMED in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 258,313 (▲ 263% vs 2024). filed late Source: NBB ↗
- New establishment in Brussel. KBO
- Start of the company according to the CBE. KBO
- Karim El Barkani became a director. NBB
- Hanane El Kenz became a director. NBB
In short
From € 50,289 profit in 2022 to € 258,313 profit in 2025.
Paid € 157,653 in corporate taxes since 2022.
Best year ever: 2025, with € 258,313 profit.
Paid out € 271,779 in dividends to the owners in total.
A new publication or filing at PHARBIOMED? We notify you, reason included.
Follow PHARBIOMEDDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARBIOMED are Karim El Barkani and Hanane El Kenz.
Directors
According to the 2025 annual accounts
Karim El Barkani
Director
since 2015
Hanane El Kenz
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Reper-Vrevenstraat 16
1020 Brussel
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0597.824.559
- VAT number
- BE 0597.824.559
- Registered office
- Reper-Vrevenstraat 16, 1020 Brussel
- Names & denominations
- PHARBIOMED
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 10 February 2015
- Peppol
- Active · Active since 7 Jan 2026
- Activities · NACE
Detailhandel in farmaceutische producten